Literature DB >> 21269504

Comparative analysis and supragenome modeling of twelve Moraxella catarrhalis clinical isolates.

Jeremiah J Davie1, Josh Earl, Stefan P W de Vries, Azad Ahmed, Fen Z Hu, Hester J Bootsma, Kim Stol, Peter W M Hermans, Robert M Wadowsky, Garth D Ehrlich, John P Hays, Anthony A Campagnari.   

Abstract

BACKGROUND: M. catarrhalis is a gram-negative, gamma-proteobacterium and an opportunistic human pathogen associated with otitis media (OM) and exacerbations of chronic obstructive pulmonary disease (COPD). With direct and indirect costs for treating these conditions annually exceeding $33 billion in the United States alone, and nearly ubiquitous resistance to beta-lactam antibiotics among M. catarrhalis clinical isolates, a greater understanding of this pathogen's genome and its variability among isolates is needed.
RESULTS: The genomic sequences of ten geographically and phenotypically diverse clinical isolates of M. catarrhalis were determined and analyzed together with two publicly available genomes. These twelve genomes were subjected to detailed comparative and predictive analyses aimed at characterizing the supragenome and understanding the metabolic and pathogenic potential of this species. A total of 2383 gene clusters were identified, of which 1755 are core with the remaining 628 clusters unevenly distributed among the twelve isolates. These findings are consistent with the distributed genome hypothesis (DGH), which posits that the species genome possesses a far greater number of genes than any single isolate. Multiple and pair-wise whole genome alignments highlight limited chromosomal re-arrangement.
CONCLUSIONS: M. catarrhalis gene content and chromosomal organization data, although supportive of the DGH, show modest overall genic diversity. These findings are in stark contrast with the reported heterogeneity of the species as a whole, as wells as to other bacterial pathogens mediating OM and COPD, providing important insight into M. catarrhalis pathogenesis that will aid in the development of novel therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269504      PMCID: PMC3045334          DOI: 10.1186/1471-2164-12-70

Source DB:  PubMed          Journal:  BMC Genomics        ISSN: 1471-2164            Impact factor:   3.969


  67 in total

1.  Cloning and characterization of Helicobacter pylori succinyl CoA:acetoacetate CoA-transferase, a novel prokaryotic member of the CoA-transferase family.

Authors:  I E Corthésy-Theulaz; G E Bergonzelli; H Henry; D Bachmann; D F Schorderet; A L Blum; L N Ornston
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  The Haemophilus influenzae capsulation gene cluster: a compound transposon.

Authors:  J S Kroll; B M Loynds; E R Moxon
Journal:  Mol Microbiol       Date:  1991-06       Impact factor: 3.501

3.  Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system.

Authors:  R K Budhani; J K Struthers
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

4.  GCUA: general codon usage analysis.

Authors:  J O McInerney
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

Review 5.  Insertion sequences.

Authors:  J Mahillon; M Chandler
Journal:  Microbiol Mol Biol Rev       Date:  1998-09       Impact factor: 11.056

6.  A protective epitope of Moraxella catarrhalis is encoded by two different genes.

Authors:  C Aebi; I Maciver; J L Latimer; L D Cope; M K Stevens; S E Thomas; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

7.  Co-variation of tRNA abundance and codon usage in Escherichia coli at different growth rates.

Authors:  H Dong; L Nilsson; C G Kurland
Journal:  J Mol Biol       Date:  1996-08-02       Impact factor: 5.469

8.  Genotypic and phenotypic relatedness of 80 strains of Branhamella catarrhalis of worldwide origin.

Authors:  J J Christensen; J Ursing; B Bruun
Journal:  FEMS Microbiol Lett       Date:  1994-06-01       Impact factor: 2.742

9.  Experimental evidence for Moraxella-induced penicillin neutralization in pneumococcal pneumonia.

Authors:  C Hol; E E Van Dijke; C M Verduin; J Verhoef; H van Dijk
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

10.  Pulmonary clearance of Moraxella catarrhalis in an animal model.

Authors:  M Unhanand; I Maciver; O Ramilo; O Arencibia-Mireles; J C Argyle; G H McCracken; E J Hansen
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

View more
  28 in total

1.  Molecular characterization of plasmid pMoma1of Moraxella macacae, a newly described bacterial pathogen of macaques.

Authors:  Chris A Whitehouse; Jason T Ladner; Gustavo F Palacios
Journal:  Folia Microbiol (Praha)       Date:  2014-11-15       Impact factor: 2.099

2.  Mobile genetic elements in Moraxella catarrhalis.

Authors:  John Hays
Journal:  Mob Genet Elements       Date:  2011-07-01

Review 3.  Panel 5: Microbiology and immunology panel.

Authors:  Timothy F Murphy; Tasnee Chonmaitree; Stephen Barenkamp; Jennelle Kyd; Johanna Nokso-Koivisto; Janak A Patel; Terho Heikkinen; Noboru Yamanaka; Pearay Ogra; W Edward Swords; Tania Sih; Melinda M Pettigrew
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

4.  A Moraxella catarrhalis two-component signal transduction system necessary for growth in liquid media affects production of two lysozyme inhibitors.

Authors:  Stephanie N Joslin; Christine Pybus; Maria Labandeira-Rey; Amanda S Evans; Ahmed S Attia; Chad A Brautigam; Eric J Hansen
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

5.  What Makes a Bacterial Species Pathogenic?:Comparative Genomic Analysis of the Genus Leptospira.

Authors:  Derrick E Fouts; Michael A Matthias; Haritha Adhikarla; Ben Adler; Luciane Amorim-Santos; Douglas E Berg; Dieter Bulach; Alejandro Buschiazzo; Yung-Fu Chang; Renee L Galloway; David A Haake; Daniel H Haft; Rudy Hartskeerl; Albert I Ko; Paul N Levett; James Matsunaga; Ariel E Mechaly; Jonathan M Monk; Ana L T Nascimento; Karen E Nelson; Bernhard Palsson; Sharon J Peacock; Mathieu Picardeau; Jessica N Ricaldi; Janjira Thaipandungpanit; Elsio A Wunder; X Frank Yang; Jun-Jie Zhang; Joseph M Vinetz
Journal:  PLoS Negl Trop Dis       Date:  2016-02-18

6.  Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars.

Authors:  Azad Ahmed; Josh Earl; Adam Retchless; Sharon L Hillier; Lorna K Rabe; Thomas L Cherpes; Evan Powell; Benjamin Janto; Rory Eutsey; N Luisa Hiller; Robert Boissy; Margaret E Dahlgren; Barry G Hall; J William Costerton; J Christopher Post; Fen Z Hu; Garth D Ehrlich
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

7.  Use of the chinchilla model for nasopharyngeal colonization to study gene expression by Moraxella catarrhalis.

Authors:  Todd C Hoopman; Wei Liu; Stephanie N Joslin; Christine Pybus; Jennifer L Sedillo; Maria Labandeira-Rey; Cassie A Laurence; Wei Wang; James A Richardson; Lauren O Bakaletz; Eric J Hansen
Journal:  Infect Immun       Date:  2011-12-19       Impact factor: 3.441

8.  Persistence of Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease and Regulation of the Hag/MID Adhesin.

Authors:  Timothy F Murphy; Aimee L Brauer; Melinda M Pettigrew; Eric R LaFontaine; Hervé Tettelin
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

9.  Genome sequence of Moraxella catarrhalis RH4, an isolate of seroresistant lineage.

Authors:  Aldert Zomer; Stefan P W de Vries; Kristian Riesbeck; Andreas L Meinke; Peter W M Hermans; Hester J Bootsma
Journal:  J Bacteriol       Date:  2012-12       Impact factor: 3.490

10.  Development of a LacZ-based transcriptional reporter system for use with Moraxella catarrhalis.

Authors:  Amanda S Evans; Christine Pybus; Eric J Hansen
Journal:  Plasmid       Date:  2012-12-04       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.